- * Males and females ages 18 - 80
- * Chronic kidney disease (CKD) - eGFR 15 to \< 60 mL/min/1.73m2 at screening
- * Hyperkalemia, defined as a serum potassium value of 5.1 to \< 6.5 mEq/L at screening
- * Taking either an Angiotensin-Converting Enzyme (ACE) Inhibitor, an Angiotensin II receptor blocker (ARB), or an aldosterone antagonist (AA) medication
- * Informed consent given
Chronic Kidney Disease (CKD)
A Two-Part, Single-Blind, Phase 3 Study Evaluating the Efficacy and Safety of Patiromer for the Treatment of Hyperkalemia (OPAL)
NCT01810939 | PHASE 3 | INTERVENTIONAL
The purpose of this study was to evaluate the efficacy and safety of patiromer (investigational drug) in the treatment of hyperkalemia (high serum potassium). The study also evaluated the effect of withdrawing patiromer treatment and assessed whether chronic treatment with patiromer prevented the recurrence of hyperkalemia. The safety of patiromer treatment was also evaluated.
Trial Information
If interested, contact clinicaltrials@cslbehring.com for more information
CSL Behring respects your privacy. For an explanation of how CSL Behring will use the information you are submitting, please view our Privacy Policy
Investigator Site
Azusa,California,United States,91702
Investigator Site
Los Angeles,California,United States,90025
Investigator Site
Sacramento,California,United States,95825
Investigator Site
Santa Barbara,California,United States,93110
Investigator Site
Ventura,California,United States,93003
Investigator Site
Edgewater,Florida,United States,32132
Investigator Site
Hollywood,Florida,United States,33021
Investigator Site
Port Charlotte,Florida,United States,33952
Investigator Site
Augusta,Georgia,United States,30909
Investigator Site
Farmington,Missouri,United States,63640
Investigator Site
Kansas City,Missouri,United States,64111
Investigator Site
Flushing,New York,United States,11355
Investigator Site
Bethlehem,Pennsylvania,United States,18017
Investigator Site
San Antonio,Texas,United States,78229
Investigator Site
Karlovac,Croatia,47000
Investigator Site
Osijek,Croatia,31000
Investigator Site
Zagreb,Croatia,10000
Investigator Site
Zagreb,Croatia,10000
Investigator Site
Zagreb,Croatia,10000
Investigator Site
Znojmo,Czechia,66902
Investigator Site
Aarhus N,Denmark,8200
Investigator Site
Fredericia,Denmark,7000
Investigator Site
Roskilde,Denmark,4000
Investigator Site
Viborg,Denmark,8800
Investigator Site
Tbilisi,Georgia,0102
Investigator Site
Tbilisi,Georgia,0144
Investigator Site
Tbilisi,Georgia,0159
Investigator Site
Tbilisi,Georgia,0159
Investigator Site
Tbilisi,Georgia,0159
Investigator Site
Tbilisi,Georgia,0159
Investigator Site
Tbilisi,Georgia,0159
Investigator Site
Tbilisi,Georgia,0159
Investigator Site
Tbilisi,Georgia,0159
Investigator Site
Tbilisi,Georgia,0159
Investigator Site
Tbilisi,Georgia,0159
Investigator Site
Tbilisi,Georgia,0186
Investigator Site
Balatonfured,Hungary,H-8230
Investigator Site
Budapest,Hungary,H-1133
Investigator Site
Gyor,Hungary,H-9024
Investigator Site
Hatvan,Hungary,H-3000
Investigator Site
Jaszbereny,Hungary,H-5100
Investigator Site
Kistarcsa,Hungary,H-2143
Investigator Site
Veszprem,Hungary,H-8200
Investigator Site
Pavia,Italy,27100
Investigator Site
Belgrade,Serbia,11000
Investigator Site
Vrsac,Serbia,26300
Investigator Site
Zrenjanin,Serbia,23000
Investigator Site
Celje,Slovenia,3000
Investigator Site
Jesenice,Slovenia,4270
Investigator Site
Ivano-Frankivsk,Ukraine,76018
Investigator Site
Kharkiv,Ukraine,61007
Investigator Site
Kharkiv,Ukraine,61018
Investigator Site
Kharkiv,Ukraine,61039
Investigator Site
Kyiv,Ukraine,04114
Investigator Site
Kyiv,Ukraine,3680
Investigator Site
Lugansk,Ukraine,91045
Investigator Site
Zaporizhzhia,Ukraine,69001
Investigator Site
Zaporizhzhia,Ukraine,69118
Study Eligibility Criteria
Additional Studies
Additional studies can be found at ClinicalTrials.gov